Cannabis during menstruation and PMS: Dysmenorrhea and endometriosis
Menstrual pain, PMS, and endometriosis are among the most common reasons why women use cannabis medicinally — and this has been the case long before legalization. The biological foundations are well understood: The endocannabinoid system is deeply integrated into the function of the uterus, ovaries, and hormonal balance. What the research shows, where cannabis can help and where caution is needed.
Overview
hide
ECS in the reproductive system: CB1 and CB2 on the uterus and ovaries
The endocannabinoid system is anatomically closely linked to the reproductive system:
- CB1 on uterine muscle: The smooth muscle of the uterus carries CB1 receptors. CB1 activation inhibits myometrium contractions — a direct point of action for the spasmolytic effect in dysmenorrhea. Endogenous anandamide release physiologically dampens excessive uterine contractions
- CB2 on endometrial tissue: CB2 is expressed in the endometrium (uterine lining) and on immune cells infiltrating the uterus. CB2 activation dampens pro-inflammatory cytokines in the endometrium — relevant for endometriosis, which is fundamentally an inflammatory disease
- FAAH in the reproductive system: The anandamide-degrading enzyme FAAH is expressed in the uterus, ovaries, and fallopian tubes. Local anandamide levels regulate implantation, ovulation, and uterine tone. CBD inhibits FAAH systemically — increased anandamide levels in reproductive tissue
- Hormonal interactions: Estrogen regulates CB1 receptor density — shortly before menstruation (high estrogen peak) CB1 density is increased. This could explain why cannabis has a more intense effect premenstrually. THC also interacts with LH pulse regulation via the hypothalamus — relevant for cycle regularity with regular use
Primary dysmenorrhea: Cannabis against menstrual pain
Primary dysmenorrhea (menstrual pain without structural cause) affects up to 80% of all women of reproductive age:
- Pathophysiology: Drop in progesterone before menstruation → release of arachidonic acid from endometrial membranes → synthesis of prostaglandin E2 and prostaglandin F2α via COX-2. Excess prostaglandins → enhanced uterine contractions, vasoconstriction, ischemia = pain
- Cannabis and Prostaglandin Inhibition: CBD inhibits COX-2 (Cyclooxygenase-2) — the key enzyme in prostaglandin synthesis. Similar mechanism as ibuprofen and other NSAIDs, but via a different binding site. THC via CB1 on uterine muscle reduces contraction strength directly
- CB1-mediated Spasmolysis: CB1 activation in the myometrium inhibits calcium influx into smooth muscle cells → less contraction. This mechanism explains the spasmolytic effect reported by many women
- Clinical Evidence: No RCTs specifically on cannabis for primary dysmenorrhea. Observational studies and surveys (e.g. Bouaziz et al. 2017) show high usage rates for menstrual pain and mostly positively evaluated effects. Placebo-controlled studies are still missing
- Application: Sublingual CBD oil or vaporizer with low-dose THC/CBD ratio. Preventive use 1–2 days before expected menstrual onset is advisable
Endometriosis: Anandamide Deficit as a Disease Mechanism
Endometriosis affects 10% of all women — and the ECS plays a central pathophysiological role:
- Anandamide deficiency in endometriosis: Sanchez et al. 2016 (Human Reproduction): Women with endometriosis had significantly lower anandamide levels in peritoneal fluid compared to healthy women. FAAH activity in endometrial lesions is increased — excessive anandamide breakdown as a possible pathomechanism
- CB2 and immunomodulation: Endometriosis is a chronic inflammatory disease — peritoneal macrophages, NK cells and mast cells play a central role in lesion maintenance and pain generation. CB2 activation by cannabinoids suppresses this immune cell activity. Reduction of IL-6, IL-8, MCP-1 in endometrial cells has been demonstrated
- Neurogenesis in lesions: Endometriosis lesions form their own nerve fibers (neurogenesis) — explains the deep, burning quality of the pain. CB1 on sensory C-fibers and Aδ-fibers: cannabinoids reduce peripheral nociceptor sensitization in lesions
- CB1 polymorphism and endometriosis risk: Studies show an association between certain CNR1 gene variants and increased endometriosis risk — indicating ECS dysfunction as a predisposing factor (Matalliotakis et al. 2008)
- Clinical evidence: Survey studies (Armour et al. 2019: n=484 Australia) show cannabis as the most commonly used plant-based self-medication for endometriosis — pain, sleep and nausea as main indications. No controlled intervention studies so far
Related
PMS and PMDS: Anxiety, mood and the ECS
Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDS) have a neurohormonal basis with ECS connection:
- Allopregnanolone and GABA: During the luteal phase, progesterone rises → breakdown into allopregnanolone → GABA-A modulation. In PMDS, the brain paradoxically reacts to allopregnanolone (anxiogenic rather than anxiolytic effect). The ECS modulates the same GABAergic circuits in the amygdala via CB1
- CBD for PMS Anxiety: CBD acts anxiolytically via 5-HT1A and GABA-A potentiation — pharmacologically targeted for PMS anxiety symptoms. No specific PMS studies, but strong evidence for CBD in anxiety in general
- THC and Mood Regulation: Low-dose THC can reduce premenstrual irritability and dysphorias. Cave: High THC doses can intensify anxiety and paranoia — counterproductive for PMDS. Dosage is crucial
- Sleep in the Luteal Phase: PMS sleep disturbances (often REM sleep disruption) can be improved with CBD/low-THC preparations — deep sleep promotion through CB1 activation
Risks and Considerations for Women
- THC and Cycle Regulation: Regular THC consumption can inhibit LH pulses (luteinizing hormone) via the hypothalamus → cycle irregularities, in rare cases anovulation with very high consumption. More relevant with daily use than with cycle-based application
- Pregnancy — absolute contraindication: Cannabis use during pregnancy is associated with lower birth weight, preterm birth, and neurobiological developmental risks. No cannabis during existing or planned pregnancy — without exception
- Estrogen and tolerance development: Estrogen increases CB1 receptor density — women may develop tolerance to THC effects more quickly than men. Cannabis-free days during the follicular phase (lower estrogen levels) may slow down tolerance development
- Hormonal contraception: No known interactions between CBD/cannabis and combined oral contraceptives (COC) via CYP3A4 in clinically relevant amounts — but CYP interactions theoretically possible at very high CBD doses
- Health insurance and endometriosis: Endometriosis with treatment-resistant pain can serve as a basis for a cannabis prescription. Involve a gynecologist or pain specialist — application with documentation of previous NSAID/hormonal therapy attempts
How cannabis modulates neuropathic and chronic pain:
Cannabis during pregnancy and breastfeeding — absolute contraindication and developmental risks:
Cannabis and sexuality — libido, dyspareunia, and orgasm: Cannabis and sexuality.
Frequently asked questions about cannabis for PMS and menstruation
Related
Cannabis for restless legs: CBD, dopamine & studies
Cannabis & bones: CB2, osteoporosis & bone healing
Cannabis & testosterone: effect on male fertility
Cannabis quality: laboratory tests, pesticides & contamination
Home cannabis cultivation: rules according to CanG
Cannabis microdosing: low doses of THC & CBD
More
CBN (cannabinol): Sleep sedative & effect explained
Cannabis for ADHD: THC, CBD & concentration - Studies
CBG (cannabigerol): effect, studies & application
Cannabis decarboxylation: activating THCA to THC
Cannabis in sport: CBD, regeneration & doping test
Cannabis & heart: cardiovascular risks explained
THC tolerance: how it develops and how to reduce it
Cannabis & immune system: CB2 receptors & inflammation
Cannabis in palliative care: pain & quality of life
Delta-8-THC & Delta-10-THC: Effect, difference & law
